Biogen to acquire ophthalmology gene therapy play Nightstar

Gene therapy platforms continue to capture the interest of large biopharma, with Biogen the latest to announce a deal. The bellwether said early Monday that it will acquire ophthalmology gene therapy company Nightstar for $877

Read the full 359 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE